Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trovocabtagene autoleucel
- Development stage
- Phase 2
- Lead developer
- AbelZeta, Inc.
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Trovocabtagene autoleucel (C-CAR088) is an autologous, second-generation chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antigen (BCMA), also known as TNFRSF17. Developed by AbelZeta (formerly Cellular Biomedicine Group), the construct incorporates a 4-1BB costimulatory domain to promote T-cell expansion and persistence. It is specifically designed for the treatment of relapsed or refractory multiple myeloma, where BCMA is highly and selectively expressed on the surface of malignant plasma cells. The therapy is currently being evaluated in Phase Ib/II clinical trials to assess safety, efficacy, and the recommended Phase II dose in patients who have failed multiple prior lines of therapy.
- Brand names
- trovo-cel
- Other names
- trovocabtagene autoleucel
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on trovocabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trovocabtagene autoleucel.